Hemab Therapeutics Elects Director Keli Walbert to Board and Audit Committee

What Happened

• Hemab Therapeutics Holdings, Inc. (COAG) announced that on September 24, 2026 its Board elected Keli Walbert as a Class I director, effective immediately. Her term expires at the 2027 annual meeting of stockholders. The Board also appointed Ms. Walbert to the Audit Committee.
• Ms. Walbert will receive compensation under the company’s non-employee director policy, including an option to purchase 36,000 shares (grant date Sept 24, 2026) at the closing stock price on that date, vesting in equal monthly installments over three years and accelerating upon a change in control. She will also receive $40,000 annually for Board service, an additional $10,000 annually for Audit Committee service, annual equity grants per policy, and reimbursement for meeting-related travel and expenses. She will enter the company’s standard indemnification agreement.

Key Details

• Director elected: Keli Walbert; effective date: September 24, 2026; term through 2027 annual meeting.
• Equity award: option for 36,000 shares; exercise price = closing price on Sept 24, 2026; monthly vesting to 3rd anniversary; full acceleration on change in control.
• Cash pay: $40,000/year (board) + $10,000/year (Audit Committee); plus annual equity grants and expense reimbursement.
• No related-party arrangements or family relationships reported; no transactions requiring Item 404 disclosure.

Why It Matters

• Board composition and committee membership affect corporate oversight; adding an Audit Committee member is directly relevant to financial governance and reporting oversight.
• The disclosed compensation (cash plus equity option) is standard for non-employee directors but creates potential future equity dilution tied to the 36,000-share option.
• Investors should note the short initial term (through the 2027 annual meeting) and the change-in-control acceleration provision, which could affect outcomes if corporate transactions occur.